EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The risk of tuberculosis infection in Saudi patients receiving adalimumab, etanercept, and tocilizumab therapy

Abdulaziz Boqaeid, Laila Layqah, Amgad Alonazy, Mutaz Althobaiti, Al-Zahraa Almahlawi, Abdullah Al-Roqy, Omar Baharoon, Abdullah Alsaeedi, Jinan Shamou, Salim Baharoon

Journal of Infection and Public Health · 2024

DOI: 10.1016/j.jiph.2024.04.016 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Infection and Public Health, 2024. Verfasst von Abdulaziz Boqaeid und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, King Abdulaziz Medical City, Riyadh, Saudi Arabia; King Abdullah International Medical Research Center, Riyadh, Saudi Arabia;…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Adalimumab, Etanercept, Tuberculosis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAdalimumabEtanerceptTuberculosisHumansSaudi ArabiaMaleFemaleRetrospective StudiesAdultMiddle AgedArthritis, RheumatoidAntirheumatic AgentsInflammatory Bowel DiseasesArthritis, JuvenileArthritis, PsoriaticYoung AdultAged

Stichwörter der Autor:innen

AdalimumabEtanerceptRheumatoid arthritisTocilizumabTuberculosis infection

Substanzen

tocilizumabAntibodies, Monoclonal, HumanizedAdalimumabEtanerceptAntirheumatic Agents

Autor:innen und Institutionen

  • Department of Medicine, King Abdulaziz Medical City, Riyadh, Saudi Arabia; King Abdullah International Medical Research Center, Riyadh, Saudi Arabia; Ministry of National Guard-Health Affairs, Riyadh, Saudi Arabia. Elec…
  • King Saud bin Abdul-Aziz University for Health Sciences, Riyadh, Saudi Arabia; Research office, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia; Ministry of National Guard-Health Affairs, Riyad…
  • Department of Medicine, King Faisal Specialized Hospital and Research Center, Riyadh, Saudi Arabia. Electronic address: alamgad96@gmail.com.
  • College of Medicine, Dar Al-Uloom University, Riyadh, Saudi Arabia. Electronic address: Baharoonomar@gmail.com.
  • Department of Medicine, Al-Jahra Hospital, Kuwait. Electronic address: alsaeedi44@hotmail.com.
  • Department of Medicine, King Abdulaziz Medical City, Riyadh, Saudi Arabia; King Abdullah International Medical Research Center, Riyadh, Saudi Arabia; King Saud bin Abdul-Aziz University for Health Sciences, Riyadh, Saud…

Zitieren

APA

Boqaeid, A., Layqah, L., Alonazy, A., Althobaiti, M., Almahlawi, A. Z., Al-Roqy, A., Baharoon, O., Alsaeedi, A., Shamou, J., & Baharoon, S. (2024). The risk of tuberculosis infection in Saudi patients receiving adalimumab, etanercept, and tocilizumab therapy. Journal of Infection and Public Health. https://doi.org/10.1016/j.jiph.2024.04.016

Vancouver

Boqaeid A, Layqah L, Alonazy A, Althobaiti M, Almahlawi AZ, Al-Roqy A, et al. The risk of tuberculosis infection in Saudi patients receiving adalimumab, etanercept, and tocilizumab therapy. Journal of Infection and Public Health. 2024. doi:10.1016/j.jiph.2024.04.016

BibTeX
@article{Boqaeid2024,
  author = {Boqaeid, Abdulaziz and Layqah, Laila and Alonazy, Amgad and Althobaiti, Mutaz and Almahlawi, Al-Zahraa and Al-Roqy, Abdullah and Baharoon, Omar and Alsaeedi, Abdullah and Shamou, Jinan and Baharoon, Salim},
  title = {The risk of tuberculosis infection in Saudi patients receiving adalimumab, etanercept, and tocilizumab therapy},
  journal = {Journal of Infection and Public Health},
  year = {2024},
  doi = {10.1016/j.jiph.2024.04.016}
}
Kostenlos starten →